Valuation: Kindstar Globalgene Technology, Inc.

Market Cap 815M 121M 104M 97.53M 89.47M 168M 11.49B 171M 1.14B 449M 5.76B 453M 443M 19.04B P/E 2024
-19.2x
P/E 2025 -17x
Enterprise Value -374M -55.45M -47.97M -44.79M -41.09M -77.29M -5.28B -78.51M -526M -206M -2.65B -208M -204M -8.74B EV / Sales 2024
-0.19x
EV / Sales 2025 -0.2x
Free-Float
48.24%
Yield 2024
2.02%
Yield 2025 8.48%
06-08 Kindstar Globalgene Technology, Inc. commences an Equity Buyback Plan for 103,426,264 shares, representing 10% of its issued share capital, under the authorization approved on June 5, 2026. CI
03-30 Kindstar Globalgene Technology posts full-year loss attributable of RMB58.7 million RE
03-29 Kindstar Globalgene Technology, Inc. announces Annual dividend, payable on August 27, 2026 CI
03-29 Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-29 Kindstar Globalgene Technology, Inc. Announces Board Appointments, Effective March 27, 2026 CI
11-25 Kindstar Globalgene Technology Inc unit to buy 40% of Huaxi Kindstar RE
25-08-28 Tranche Update on Kindstar Globalgene Technology, Inc.'s Equity Buyback Plan announced on June 5, 2024. CI
25-08-28 Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-08-28 Kindstar Globalgene Technology, Inc. Announces Company Secretary Changes, Effective August 29, 2025 CI
25-08-22 Kindstar Globalgene Technology expects HY net loss of RMB30-35 million RE
25-08-22 Kindstar Globalgene Technology, Inc. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2025 CI
25-06-05 Kindstar Globalgene Technology, Inc. Approves Dividend for the Year Ended December 31, 2024 CI
25-06-04 Kindstar Globalgene Technology, Inc.'s Equity Buyback announced on June 5, 2024, has expired with 5,506,000 shares, representing 0.58% for HKD 10.13 million. CI
Manager TitleAgeSince
Chief Executive Officer 68 2021-02-07
Director of Finance/CFO 48 2021-02-07
Chief Tech/Sci/R&D Officer - 2024-09-26
Director TitleAgeSince
Director/Board Member 60 2012-01-29
Director/Board Member 65 2026-03-26
Director/Board Member 61 2021-02-22
Change 5-day change 1-year change 3-year change Capi.($)
+0.43%+7.47% - - 121M
+21.37%+20.29%+111.98%+510.96% 46.26B
+0.83%+3.22%+20.06%+49.24% 25.88B
+0.04%+1.78%-19.56%-35.04% 7.76B
+6.20%+13.49%+35.65%+128.20% 5.69B
+0.19%+1.39%+21.09%+63.03% 3.39B
+10.76%+18.38%-26.68%+1,059.10% 2.3B
+6.49%+8.37%+185.69%+8.16% 2.13B
+11.67%+10.56%+32.06%+23.05% 2.02B
+3.35%+4.36%-4.07%-55.62% 1.99B
Average +6.13%+8.67%+39.58%+194.56% 10.83B
Weighted average by Cap. +11.43%+12.13%+63.76%+287.08%

Financials

2024 2025
Net sales 928M 137M 119M 111M 102M 192M 13.08B 195M 1.3B 511M 6.56B 516M 505M 21.68B 934M 138M 120M 112M 103M 193M 13.17B 196M 1.31B 515M 6.6B 519M 508M 21.82B
Net income -54.59M -8.09M -7M -6.53M -5.99M -11.27M -770M -11.45M -76.66M -30.09M -386M -30.38M -29.71M -1.28B -58.74M -8.7M -7.53M -7.03M -6.45M -12.13M -828M -12.32M -82.49M -32.38M -415M -32.69M -31.97M -1.37B
Net Debt -1.26B -186M -161M -151M -138M -260M -17.73B -264M -1.77B -693M -8.89B -700M -684M -29.38B -1.19B -176M -152M -142M -131M -246M -16.77B -249M -1.67B -655M -8.4B -662M -647M -27.79B
Logo Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology Inc is an investment holding company engaged in the provision of clinical testing services. The Company includes nine segments. The Hematology Testing segment includes testing services related to blood diseases. The Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. The Infectious Diseases segment includes testing services from the infection department. The Oncology segment includes testing related to oncology diseases. The Neurology segment includes testing services related to neurological diseases. The Maternity-Related Diseases segment includes testing services related to maternity. The Routine Testing segment conducts routine tests for the doctors’ daily diagnoses. The Scientific Research Services and Cro segment includes research and development services. The Others segment provides other miscellaneous testing services.
Employees
3,100